Witryna28 wrz 2024 · The occurrence of irAEs in the immunotherapy arm was 41% in IMpower133, which is higher than historical data, and 20% in the CASPIAN trial. A … Witryna肺癌 IMpower133 各領域で発表されている臨床試験を分かりやすくサマライズして掲載しています アカデミアによる臓器横断的ながん治療情報サイト
IMPOWER133: UPDATED OVERALL SURVIVAL (OS) ANALYSIS OF …
Witryna4 cze 2024 · IMpower133研究是20年来,第一个组广泛期SCLC一线治疗上,观察到超越标准治疗方案,取得有临床意义OS改善的研究。 相比于单纯EP化疗,在EP方案的基础上联合atezo用于未经选择的广泛期SCLC一线治疗,可以显著延长PFS和OS。 与预期一致,atezo联合EP方案,未观察到预期以外的安全性事件,包括接受PCI或胸部放疗的 … WitrynaIn this interim analysis, safety data observed in the induction phase seem consistent with IMpower133 results considering a patient population closer to clinical practice both for baseline patient characteristics and co-treatments allowed. In terms of efficacy data, we found that PFS and ORR were also aligned. track smsa shipment
WCLC热议Impower133和Caspian在ES-SCLC的王者之争 - CN …
Witryna16 wrz 2024 · In IMpower133, investigators assessed the safety and efficacy of the addition of atezolizumab, an inhibitor of PD-L1, versus placebo to first-line carboplatin and etoposide in four 21-day cycles, followed by a maintenance of atezolizumab versus placebo based on the initial randomization, in a 1:1 double-blind randomization of 403 … WitrynaIMpower133及CASPIAN研究在ES-SCLC患者一线治疗中均取得了总生存期(overall survival, OS)的突破性进展,由此FDA批准PD-L1单克隆抗体Atezolizumab(阿特珠单抗)[8]及Durvalumab(德瓦鲁单抗)[9]与卡铂和依托泊苷联合用于ES-SCLC患者的一线治 … Witryna11 kwi 2024 · 阿替利珠单抗 的Impower133研究整体结果显示,中位生存期OS可延长2个月,达到12.3个月,其中肝转移亚组的患者也可降低19%的死亡风险。 度伐利尤单抗的CASPIAN研究整体结果显示,中位OS可达到13.0个月,其中胸外转移亚组(肝转移占比52.8%)可降低23%的死亡风险。 c. 免疫+抗血管+化疗 IMpower150研究对比了 阿 … the rome club